- Home
- CYRX vs CRVS Comparison
CYRX vs CRVS Comparison
Compare CYRX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- CRVS
- Stock Information
- Founded
- CYRX 1999
- CRVS 2014
- Country
- CYRX United States
- CRVS United States
- Employees
- CYRX N/A
- CRVS N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- CRVS Health Care
- Exchange
- CYRX Nasdaq
- CRVS Nasdaq
- Market Cap
- CYRX 405.4M
- CRVS 451.0M
- IPO Year
- CYRX N/A
- CRVS 2016
- Fundamental
- Price
- CYRX $6.55
- CRVS $8.98
- Analyst Decision
- CYRX Buy
- CRVS Buy
- Analyst Count
- CYRX 7
- CRVS 4
- Target Price
- CYRX $13.14
- CRVS $12.83
- AVG Volume (30 Days)
- CYRX 416.3K
- CRVS 1.1M
- Earning Date
- CYRX 11-07-2024
- CRVS 11-12-2024
- Dividend Yield
- CYRX N/A
- CRVS N/A
- EPS Growth
- CYRX N/A
- CRVS N/A
- EPS
- CYRX N/A
- CRVS N/A
- Revenue
- CYRX $226,113,000.00
- CRVS N/A
- Revenue This Year
- CYRX $0.34
- CRVS N/A
- Revenue Next Year
- CYRX $8.47
- CRVS N/A
- P/E Ratio
- CYRX N/A
- CRVS N/A
- Revenue Growth
- CYRX N/A
- CRVS N/A
- 52 Week Low
- CYRX $5.32
- CRVS $1.30
- 52 Week High
- CYRX $20.11
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CYRX 36.27
- CRVS 51.92
- Support Level
- CYRX $7.18
- CRVS $8.02
- Resistance Level
- CYRX $8.79
- CRVS $8.71
- Average True Range (ATR)
- CYRX 0.61
- CRVS 0.80
- MACD
- CYRX -0.12
- CRVS -0.21
- Stochastic Oscillator
- CYRX 0.00
- CRVS 20.72
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).